By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11025 Roselle Street
Suite 200
San Diego  California  92121  U.S.A.
Phone: 858-587-5870 Fax: 858-587-5871


Company News
Study Supports Diagnostic Utility Of bioTheranostics’ CancerTYPE ID Molecular Cancer Classifier In Cytology & Limited Tissue Samples 5/19/2016 10:56:39 AM
bioTheranostics' Chief Scientific Officer Nominated For Athena Pinnacle Award 4/29/2016 10:23:34 AM
bioTheranostics To Present Feasibility Data Of Gene Expression Profiling In Blood 4/19/2016 12:03:31 PM
SoCal's bioTheranostics Rakes In $32 Million for Cancer Diagnostics 1/21/2016 6:55:09 AM
bioTheranostics Release: Studies Demonstrate Broadening Clinical Utility Of Biotheranostics’ Breast Cancer Index Molecular Test In The Extended Endocrine Therapy Setting 12/8/2015 1:22:49 PM
Yale University Study Shows bioTheranostics’ Breast Cancer Indexsm Molecular Test Impacts Extended Endocrine Therapy Decisions In Clinical Practice 12/8/2015 12:44:16 PM
bioTheranostics Announces Collaboration With DeNovo Sciences To Evaluate Its Proprietary Cancer Biomarkers For Use In Liquid Biopsies 10/6/2015 10:49:17 AM
Journal Of The National Comprehensive Cancer Network Review Article Highlights Role Of bioTheranostics’ Breast Cancer Index In Optimizing Endocrine Therapy 9/16/2015 11:56:26 AM
ASCO15: Studies Presented At 2015 ASCO Meeting Demonstrate Predictive Power Of bioTheranostics’ Breast Cancer Index Molecular Test In Endocrine Therapy Decisions 6/1/2015 2:20:30 PM
ASCO Conference Data Show bioTheranostics’ Molecular Tests Significantly Impact Management Of Metastatic Cancer Patients 5/28/2015 11:01:29 AM